Topical treatment numerically reduced progression to treatment-requiring retinopathy of prematurity in a randomized trial, although the primary endpoint was not met.
A prospective multicenter study found improvements in ocular surface integrity, tear-film stability, tear production, and symptom burden over 60 days in patients with moderate-to-severe dry eye disease.
A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.